# Opiate Conversion Calculator โ Clinical Tool Protocol

**Guidelines Referenced:**  
CDC Guideline for Prescribing Opioids for Chronic Pain 2022, American Pain Society Principles of Analgesic Use 2016, FDA Guidance for Industry on Abuse-Deterrent Opioids 2022, Joint Commission Standards for Pain Assessment and Management 2023

**Official Sources:**  
https://www.cdc.gov/drugoverdose/prescribing/guideline.html  
https://www.americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf  
https://www.fda.gov/regulatory-information/search-fda-guidance-documents

## CARD INTERFACE LAYOUT

### Card 0 โ Dynamic Action Card (Node Dependent)

**Need Opioid Conversion Node:**

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ OPIOID CONVERSION TYPE SELECTION                            โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ ๐ CONVERSION INDICATION: Route change for NPO patient      โ
โ Current medication: Morphine 30mg PO q4h                   โ
โ                                                           โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ โ     CONVERSION OPTIONS          โ                        โ
โ โ                                โ                        โ
โ โ โ ROUTE CHANGE (Same Drug)      โ [Simple ratio conversion]โ
โ โ   โข PO to IV for NPO patients   โ [No cross-tolerance]   โ
โ โ   โข IV to PO for discharge      โ [Standard ratios]      โ
โ โ   โข Apply bioavailability ratiosโ [Safety verification] โ
โ โ                                โ                        โ
โ โ โ OPIOID ROTATION (Different)   โ [Cross-tolerance risk] โ
โ โ   โข For side effects/tolerance  โ [25-50% reduction]     โ
โ โ   โข Requires safety reduction   โ [Conservative start]   โ
โ โ   โข Start low, titrate up       โ [Monitor closely]      โ
โ โ                                โ                        โ
โ โ โ LONG-ACTING CONVERSION        โ [Tolerance required]   โ
โ โ   โข Stable chronic pain only    โ [โฅ60 MME daily]       โ
โ โ   โข Opioid tolerance confirmed  โ [Calculate baseline]   โ
โ โ   โข Calculate total daily MME   โ [Not for acute pain]   โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ                                                           โ
โ โ๏ธ SAFETY ALERT: Always start conservative with rotations  โ
โ Patient factors: Age 65, CrCl 45, no liver disease       โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

**Route Conversion Node:**

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ ROUTE CONVERSION RATIOS                                     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ SAME OPIOID - DIFFERENT ROUTE                              โ
โ Apply bioavailability differences only                     โ
โ                                                           โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ โ     STANDARD RATIOS             โ                        โ
โ โ                                โ                        โ
โ โ MORPHINE PO:IV = 3:1           โ                        โ
โ โ Example: 30mg PO = 10mg IV      โ                        โ
โ โ Calculation: 30mg รท 3 = 10mg    โ                        โ
โ โ                                โ                        โ
โ โ HYDROMORPHONE PO:IV = 4:1       โ                        โ
โ โ Example: 8mg PO = 2mg IV        โ                        โ
โ โ Calculation: 8mg รท 4 = 2mg      โ                        โ
โ โ                                โ                        โ
โ โ OXYCODONE PO:IV = 1.5:1         โ                        โ
โ โ Example: 15mg PO = 10mg IV      โ                        โ
โ โ Calculation: 15mg รท 1.5 = 10mg  โ                        โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ                                                           โ
โ NO DOSE REDUCTION NEEDED                                   โ
โ Same drug = same receptor binding                          โ
โ Only bioavailability difference                            โ
โ                                                           โ
โ MONITORING: Same as original medication                    โ
โ Expected effect: Equivalent analgesia                      โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

**Cross-Tolerance Node:**

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ OPIOID ROTATION SAFETY REDUCTION                           โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ INCOMPLETE CROSS-TOLERANCE REQUIRES DOSE REDUCTION         โ
โ                                                           โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ โ   REDUCTION RECOMMENDATIONS     โ                        โ
โ โ                                โ                        โ
โ โ STANDARD REDUCTION: 25-50%      โ                        โ
โ โ Use 75% of calculated dose      โ                        โ
โ โ                                โ                        โ
โ โ HIGHER REDUCTION (50%) if:      โ                        โ
โ โ โข Age >65 years                 โ                        โ
โ โ โข CrCl <30 mL/min              โ                        โ
โ โ โข Multiple sedatives           โ                        โ
โ โ โข Liver disease (Child B/C)    โ                        โ
โ โ โข Frail/debilitated            โ                        โ
โ โ                                โ                        โ
โ โ TITRATION SCHEDULE:             โ                        โ
โ โ โข Start at reduced dose         โ                        โ
โ โ โข Titrate every 24-48 hours     โ                        โ
โ โ โข Have breakthrough available   โ                        โ
โ โ โข Monitor for side effects      โ                        โ
โ โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ                        โ
โ                                                           โ
โ RATIONALE: Different opioids have varying receptor        โ
โ affinities and individual pharmacogenomic responses       โ
โ                                                           โ
โ SAFETY MONITORING:                                         โ
โ โข Respiratory rate, sedation level                        โ
โ โข Pain scores, functional improvement                      โ
โ โข Side effects (nausea, constipation)                     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

### Card 1 โ Static Assessment/MME Conversion Factors

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ MORPHINE MILLIGRAM EQUIVALENTS (MME) FACTORS               โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ ๐ ORAL OPIOID CONVERSION FACTORS:                         โ
โ                                                           โ
โ WEAK OPIOIDS:                                              โ
โ โข Codeine: 0.15 (30mg codeine = 4.5 MME)                  โ
โ โข Tramadol: 0.1 (100mg tramadol = 10 MME)                 โ
โ                                                           โ
โ MODERATE OPIOIDS:                                          โ
โ โข Morphine: 1.0 (baseline comparison)                      โ
โ โข Hydrocodone: 1.0 (10mg = 10 MME)                        โ
โ โข Oxycodone: 1.5 (10mg = 15 MME)                          โ
โ                                                           โ
โ STRONG OPIOIDS:                                            โ
โ โข Hydromorphone: 4.0 (2mg = 8 MME)                        โ
โ โข Oxymorphone: 3.0 (5mg = 15 MME)                         โ
โ โข Methadone: Variable (see complex dosing)                โ
โ                                                           โ
โ TRANSDERMAL FENTANYL:                                      โ
โ โข Conversion factor: 2.4                                   โ
โ โข 12 mcg/hr patch = 28.8 MME daily                        โ
โ โข 25 mcg/hr patch = 60 MME daily                          โ
โ โข 50 mcg/hr patch = 120 MME daily                         โ
โ โข 75 mcg/hr patch = 180 MME daily                         โ
โ โข 100 mcg/hr patch = 240 MME daily                        โ
โ                                                           โ
โ โ๏ธ METHADONE SPECIAL DOSING:                               โ
โ Complex pharmacokinetics require specialist consultation   โ
โ โข <30 MME daily: 4:1 ratio (morphine:methadone)           โ
โ โข 30-99 MME daily: 8:1 ratio                              โ
โ โข โฅ100 MME daily: 12:1 ratio                              โ
โ โข Always reduce by 75-90% and titrate slowly              โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

### Card 2 โ Static Physical Exam/Special Populations

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ SPECIAL POPULATIONS & SAFETY CONSIDERATIONS                โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ ๐ PRE-CONVERSION ASSESSMENT:                              โ
โ โข Current pain level, functional status                    โ
โ โข Respiratory rate, oxygen saturation                      โ
โ โข Mental status, sedation level                            โ
โ โข Vital signs, renal/hepatic function                      โ
โ                                                           โ
โ ๐ด ELDERLY PATIENTS (>65 years):                           โ
โ โข Start 25-50% lower than calculated dose                  โ
โ โข Longer dosing intervals initially                        โ
โ โข Avoid long-acting formulations initially                 โ
โ โข Higher risk of falls, confusion, constipation            โ
โ                                                           โ
โ ๐ฉบ RENAL IMPAIRMENT:                                       โ
โ โข CrCl <30: Avoid morphine, codeine (toxic metabolites)   โ
โ โข Safe options: Fentanyl, methadone, buprenorphine        โ
โ โข Caution with hydromorphone (reduce dose 50%)            โ
โ โข Monitor for prolonged effects                            โ
โ                                                           โ
โ ๐ซ HEPATIC IMPAIRMENT:                                     โ
โ โข Child-Pugh B/C: Reduce doses 25-50%                     โ
โ โข Increase dosing intervals                                โ
โ โข Avoid long-acting formulations                           โ
โ โข Monitor sedation closely                                 โ
โ                                                           โ
โ ๐ซ OPIOID-NAIVE PATIENTS:                                  โ
โ Never initiate with:                                       โ
โ โข Fentanyl patches (requires tolerance)                    โ
โ โข Methadone (complex dosing)                               โ
โ โข Extended-release formulations                            โ
โ โข Start with immediate-release, low doses                  โ
โ                                                           โ
โ โ๏ธ DRUG INTERACTIONS:                                       โ
โ โข Benzodiazepines: Increase respiratory depression         โ
โ โข SNRIs: Risk of serotonin syndrome                        โ
โ โข CYP3A4 inhibitors: Affect fentanyl/methadone levels     โ
โ โข Monitor closely with any CNS depressants                 โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

## FLOWCHART (Algorithm Decision Tree)

~~~mermaid
graph TD
    A[Need Opioid Conversion] --> B{Conversion Type?}
    
    B -->|Route Change| C[Apply Standard Ratios Same Drug]
    B -->|Opioid Rotation| D[Calculate MME Different Drug]
    B -->|Long-Acting| E[Assess Opioid Tolerance]
    
    C --> F[No Dose Reduction Needed]
    
    D --> G[Apply 25-50% Safety Reduction]
    
    E --> H{โฅ60 MME Daily?}
    
    H -->|Yes| I[Calculate Patch/LA Dose]
    H -->|No| J[Not Candidate Use IR Only]
    
    F --> K[Implement New Regimen Monitor]
    G --> L[Start Conservative Titrate Up]
    I --> M[Overlap Period 12-18hr]
    
    K --> N{Adequate Analgesia?}
    L --> N
    M --> N
    
    N -->|Yes| O[Continue Current Regimen]
    N -->|No| P[Assess for Adjustment]
    
    P --> Q{Side Effects Present?}
    
    Q -->|Yes| R[Reduce Dose or Change Agent]
    Q -->|No| S[Increase Dose by 25-50%]
    
    R --> T[Monitor Response]
    S --> T
    
    T --> U{Goal Achieved?}
    
    U -->|Yes| V[Stable Regimen Reached]
    U -->|No| W[Reassess Strategy]
~~~

## NODE-TO-DYNAMIC CARD PROMPT MAPPING (WITH INTERACTIVES)

| **Step (Node)**                    | **Dynamic Card Prompt/Question**                                                                 | **Interactive Components**                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| Need Conversion Recognition         | "Opioid conversion required. Select conversion type: route change, rotation, or long-acting?"   | [Conversion Type Selection], [Patient Assessment], [History Review]|
| Route Change Pathway                | "Same opioid, different route selected. Apply standard bioavailability ratios?"                | [Ratio Calculator], [Dose Verification], [No Reduction Needed]    |
| Opioid Rotation Pathway             | "Converting to different opioid. Calculate MME and apply safety reduction?"                     | [MME Calculator], [Safety Reduction], [Cross-Tolerance Warning]   |
| Long-Acting Assessment              | "Long-acting conversion requested. Confirm opioid tolerance โฅ60 MME daily?"                     | [Tolerance Verification], [Daily MME Total], [Candidacy Check]    |
| MME Calculation                     | "Calculate total daily MME using conversion factors for current regimen?"                       | [Drug Selection], [Dose Entry], [MME Calculator], [Risk Level]    |
| Safety Reduction Application        | "Apply 25-50% reduction for opioid rotation based on patient risk factors?"                    | [Risk Assessment], [Reduction Calculator], [Patient Factors]      |
| Route Ratio Application             | "Apply standard PO:IV ratios for route conversion without dose reduction?"                     | [Ratio Selection], [Calculation Display], [Dose Confirmation]     |
| Long-Acting Calculation             | "Calculate long-acting dose with appropriate overlap period for transition?"                    | [LA Dosing], [Overlap Timer], [Transition Protocol]               |
| Implementation Monitoring           | "New regimen implemented. Monitor for efficacy and side effects?"                              | [Pain Assessment], [Side Effect Check], [Monitoring Schedule]     |
| Efficacy Assessment                 | "Evaluate pain control and functional improvement with new regimen?"                           | [Pain Scores], [Function Scale], [Patient Satisfaction]          |
| Dose Adjustment Decision            | "Inadequate analgesia identified. Assess for dose increase or alternative strategy?"           | [Adjustment Calculator], [Alternative Options], [Safety Check]    |
| Side Effect Management              | "Side effects present. Consider dose reduction or agent change?"                               | [Side Effect Assessment], [Dose Reduction], [Alternative Agents]  |
| Titration Protocol                  | "Adjust dose by 25-50% based on response. Schedule next assessment?"                          | [Titration Calculator], [Schedule Next], [Monitoring Alerts]      |

**Interactive Highlights:**  
- MME calculator: real-time total with risk level display
- Conversion calculator: automated dose calculations with safety verification
- Patient risk assessment: interactive screening for reduction factors
- Monitoring scheduler: automated follow-up reminders and assessment prompts
- Drug interaction checker: alerts for dangerous combinations

## INTERACTIVE ELEMENTS

### Quick MME Calculator

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ         TOTAL DAILY MME CALCULATOR      โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ Enter Current Medications:              โ
โ                                         โ
โ Drug         Dose      ร Factor = MME   โ
โ Oxycodone   [20mg q6h] ร 1.5   = 120   โ
โ Tramadol    [100mg BID] ร 0.1   = 20    โ
โ Morphine    [15mg q4h] ร 1.0   = 90     โ
โ                                         โ
โ TOTAL DAILY MME: 230                    โ
โ                                         โ
โ ๐ด RISK LEVEL: HIGH (>90 MME)           โ
โ โข Increased overdose risk                โ
โ โข Consider dose reduction               โ
โ โข Enhanced monitoring required          โ
โ                                         โ
โ [ADD MEDICATION] [CALCULATE] [RESET]    โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

### Opioid Rotation Calculator

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ      OPIOID ROTATION CALCULATOR         โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ FROM: Morphine 180 MME daily            โ
โ TO: Hydromorphone                       โ
โ                                         โ
โ CALCULATION STEPS:                      โ
โ Step 1: Current MME = 180               โ
โ Step 2: Convert factor (รท4) = 45mg      โ
โ Step 3: Safety reduction (ร0.75) = 34mg โ
โ Step 4: Round down = 30mg daily         โ
โ                                         โ
โ NEW REGIMEN SUGGESTION:                 โ
โ Hydromorphone 5mg PO q6h                โ
โ (Total: 20mg daily for safety)         โ
โ                                         โ
โ BREAKTHROUGH:                           โ
โ Hydromorphone 1mg PO q2h PRN            โ
โ (10% of daily dose)                     โ
โ                                         โ
โ โ๏ธ Start conservative, titrate up        โ
โ                                         โ
โ [CALCULATE ROTATION] [PRINT ORDERS]     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

### Fentanyl Patch Converter

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ     FENTANYL PATCH CALCULATOR           โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ Current total MME: 180 from PO opioids  โ
โ                                         โ
โ PATCH CONVERSION:                       โ
โ 180 MME รท 2.4 = 75 mcg/hr              โ
โ                                         โ
โ RECOMMENDED PATCH: 50-75 mcg/hr         โ
โ Start with: 50 mcg/hr (conservative)    โ
โ                                         โ
โ TRANSITION PROTOCOL:                    โ
โ โข Apply patch, continue PO ร 12 hours   โ
โ โข Then discontinue oral opioids         โ
โ โข Full effect achieved in 24-48 hours   โ
โ                                         โ
โ BREAKTHROUGH COVERAGE:                  โ
โ Morphine 15mg PO q2h PRN                โ
โ (10% of daily MME requirement)          โ
โ                                         โ
โ โ๏ธ REQUIRES OPIOID TOLERANCE             โ
โ Never use in opioid-naive patients      โ
โ                                         โ
โ [CALCULATE PATCH] [TRANSITION ORDERS]   โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

### Special Population Dosing Assistant

~~~
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
โ    SPECIAL POPULATION DOSE ADJUSTOR     โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโค
โ PATIENT FACTORS:                        โ
โ Age: 78 years โ๏ธ                        โ
โ CrCl: 35 mL/min โ๏ธ                      โ
โ Liver: Normal โ                         โ
โ Concurrent sedatives: Lorazepam โ๏ธ       โ
โ                                         โ
โ RISK FACTORS IDENTIFIED: 3              โ
โ                                         โ
โ RECOMMENDED ADJUSTMENTS:                โ
โ โข Reduce calculated dose by 50%         โ
โ โข Start with longer intervals           โ
โ โข Avoid long-acting formulations        โ
โ โข Enhanced monitoring required          โ
โ                                         โ
โ STANDARD DOSE: 30mg daily               โ
โ ADJUSTED DOSE: 15mg daily               โ
โ                                         โ
โ SUGGESTED REGIMEN:                      โ
โ Morphine 2.5mg PO q6h                   โ
โ Breakthrough: 2.5mg PO q2h PRN          โ
โ                                         โ
โ [APPLY ADJUSTMENTS] [PRINT PROTOCOL]    โ
โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
~~~

## VIRTUA VOORHEES PAIN MANAGEMENT ADDENDA

- **Pain Service Consultation:** 24/7 availability via Transfer Center 856-886-5111 for complex conversions and high-risk patients
- **Pharmacy Clinical Support:** Dedicated pain pharmacist available for dosing verification and drug interaction screening
- **Quality Metrics:** Conversion accuracy rates, patient safety events, pain control effectiveness, opioid stewardship compliance
- **Electronic Calculator Integration:** Built-in EMR calculator tools with automatic alerts for high-risk conversions and interactions

## REFERENCE (GUIDELINE & SOURCE)
Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Chronic Pain. 2022.  
https://www.cdc.gov/drugoverdose/prescribing/guideline.html

**Additional References:**  
American Pain Society. Principles of Analgesic Use. 8th Edition. 2016.  
https://www.americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf

Joint Commission. Standards for Pain Assessment and Management. 2023.  
https://www.jointcommission.org/standards/standard-faqs/hospital-and-hospital-clinics/

Food and Drug Administration. Guidance for Industry: Abuse-Deterrent Opioids. 2022.  
https://www.fda.gov/regulatory-information/search-fda-guidance-documents

**All calculations follow evidence-based conversion protocols with mandatory safety reductions for opioid rotations and enhanced monitoring for high-risk populations to ensure safe and effective pain management.**
